Central Nervous System Neoplasms, Primary, Lymphoma, Large B-Cell, Diffuse
Conditions
Keywords
Lymphoma, Nervous System, Primary
Brief summary
This study is to improve the first-line induction chemotherapy, by combining either Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type (Rituximab-Methotrexate-Procarbazine-Vincristine). This is a randomized Phase II trial, preceded by a dose escalation phase Ib. The objective of the phase Ib is to rule out any limiting toxicity of the new treatment associations, and to determine the recommended dose of Lenalidomide and Ibrutinib to be used in the phase II. In the phase II study, patients will receive 4 cycles of R-MPV + Lenalidomide or 4 cycles of R-MPV + Ibrutinib. The therapeutic response will be evaluated after the 2nd and the 4th cycle. Patients in good therapeutic response will proceed to the consolidation phase with Autologous Stem Cell Transplantation (ASCT).
Detailed description
The objective of this proposal is to test the feasibility and efficacy of two targeted induction chemotherapies obtained by adding either Lenalidomide or Ibrutinib to a standard Rituximab-High Dose (HD) Methotrexate (MTX) based induction chemotherapy regimen. The R-MPV regimen is chosen as the backbone chemotherapy because of its wide use with robust reproducible results and a good and manageable toxicity profile
Interventions
DRUGLenalidomide
Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
DRUGIbrutinib
Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
Sponsors
National Cancer Institute, France
Institut Curie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Newly diagnosed Primary Central Nervous System Lymphoma (PCNSL). 2. a) Aged between 18 and 60 (\>18 and \< 60) - phase IB b) Aged between 18 and 65 (≥ 18 and ≤ 65) - phase II. 3. Histological confirmed diagnosis of Primary central nervous system lymphoma of Diffuse Large B-Cell Lymphomas (DLBCL) type OR patients with a measurable typical cerebral lesion on MRI with a diagnosis made by cytology and/or by flow cytometry on the vitreous or on the cerebral spinal fluid. 4. Measurable lesion on MRI with gadolinium enhancement. 5. Adequate hematological, renal and hepatic function (Laboratory Parameters realized within 14 days before inclusion): 1. Absolute neutrophil count (ANC) \>1000/mm3 2. Platelets \> 100,000/mm3 independent of transfusion support 3. Alanine aminotransferase and aspartate aminotransferase ≤ 3 x Upper Limit of Normal (ULN) 4. Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin 5. Estimated Glomerular Filtration Rate ≥ 60 mL/min/1.73m2. 6. Able to swallow capsules. 7. Karnofsky performance status: 40-100% for the phase IB and no restriction on the KPS for the phase II. 8. Able to understand teratogenic risks of the Lenalidomide and Ibrutinib. Patient must be able to understand and fulfill the Lenalidomide Pregnancy Prevention Plan requirements. This plan may be accepted by the person of confidence in case of impaired cognitive status of the patient. 9. Women of childbearing potential (WCBP)\* and men who are sexually active must be practicing a highly effective method\*\* of birth control. Women should avoid a pregnancy while taking treatment by Lenalidomide or Ibrutinib and for up to 1 month after ending treatment. Men must agree to not to father a child or donate sperm during treatment by Lenalidomide or Ibrutinib and up to 3 months after the last dose of study drug. 10. Women of childbearing potential (WCBP)\* must have a negative serum (beta-human chorionic gonadotropin \[B-hCG\]) or urine pregnancy test at inclusion. 11. Signed informed consent, which could be signed by a person on confidence in case the neurologic status of the patient does not allow him to understand and/or to sign.
Exclusion criteria
1. Histology other than DLBCL. 2. Positive HIV serology. 3. Active viral infection with Hepatitis B or C virus. 4. Preexisting immunodeficiency and/or organ transplant recipient. 5. Isolated Central Nervous System (CNS) relapse of systemic Non-Hodgkin's Lymphoma. 6. Prior treatment for PCNSL (except corticosteroids). 7. Isolated primary vitreo-retinal lymphoma. 8. Major surgery, within 4 weeks prior to the first dose of study drug. Stereotactic biopsy and vitrectomy are not considered major surgery. 9. History of stroke or intracranial hemorrhage (except minor post biopsy hemorrhage) within 6 months prior to inclusion. 10. Requires anticoagulation with warfarin or equivalent vitamin K antagonists. 11. Requires treatment with strong CYP3A4 inhibitors. 12. Pregnancy or lactation. 13. Clinically significant cardiovascular disease. 14. Any other active malignancy, except basocellular carcinoma and non-invasive cervix cancer. 15. Inclusion in another experimental anti-cancer drug therapy. 16. No social security affiliation. 17. Persons under legal protection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicity (DLT) during the first cycle of treatment for each treatment arm. | 1 month | Occurrence of a Dose Limiting Toxicity (DLT) during the first cycle of treatment for each treatment arm. The phase Ib is a 3+3 dose escalation design |
| Complete Response (CR) rate including unconfirmed Complete Response (uCR) at the end of the 4 cycles of induction therapy | 4 months | The primary endpoint for the phase II part of the study is the Complete Response (CR) rate including unconfirmed CR (CR+uCR) at the end of the 4 cycles of induction therapy. Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response (CR + uCR + Partial Response(PR)), stable disease (SD), and primary refractory patients (PD) after 4 cycles of induction treatment | 4 months | Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) |
| Overall Survival (OS) | 142 months | Overall Survival (OS) will be calculated from the date of randomization to the date of death, whatever the cause. Patients alive at the date of last contact will be censored at this date. |
| Response rates (CR + uCR) after 2 cycles of induction treatment | 2 months | Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) |
| The severity of the toxicity of treatment induction or ASCT | 7 months | Toxicity of treatment induction or ASCT will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 5.0) whenever possible and described by system organ class, preferred term |
| Patients who will receive ASCT | 7 months | The percentage of patients who will receive ASCT will be presented |
| Progression-Free Survival (PFS) | 142 months | Progression-Free Survival (PFS) will be calculated from the date of randomization to the date of progression or death (if the patient does not progress). Patients alive without progression at the date of last contact will be censored at this date |
| Overall response (CR + uCR + Partial Response(PR)), stable disease (SD), and primary refractory patients (PD) after 2 cycles of induction treatment | 2 months | Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) |
Countries
France
Outcome results
None listed